PRALUENT (alirocumab) ICD-10 Pocket Guide

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "PRALUENT (alirocumab) ICD-10 Pocket Guide"

Transcription

1 PRALUENT (alirocumab) ICD-10 Pocket Guide Your guide to ICD-10 coding for clinical atherosclerotic cardiovascular disease (ASCVD) INDICATION AND USAGE PRALUENT (alirocumab) is a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) inhibitor antibody indicated as adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL-C. The effect of PRALUENT on cardiovascular morbidity and mortality has not been determined. PRALUENT is contraindicated in patients with a history of a serious hypersensitivity reaction to PRALUENT. Reactions have included hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization.

2 For additional support with ICD-10 coding, call PRALUENT ( ) and select 1, or contact your PRALUENT (alirocumab) field access specialist. Table of Contents ASCVD: Coronary Heart Disease Arteriosclerotic Heart Disease 4 With Angina 4 Other 5 Acute Coronary Syndromes 5 Myocardial Infarction 5 Acute, Active 5 History of Heart Attack (old) 5 Angina 5 Coronary Revascularization 5 ASCVD: Cerebrovascular Arteriosclerotic Cerebrovascular Disease 6 Ischemic Stroke 7 Transient Ischemic Attack (TIA) 9 History of Ischemic Stroke 10 With Residuals 10 Without Residuals 10 ASCVD: Peripheral Vascular Atherosclerosis of Peripheral and Other Non-coronary, Non-cerebral Vessels 11 Peripheral Artery Revascularization 19 Please use as many clinical ASCVD codes as needed to appropriately describe your patient s condition. Brought to you by Sanofi and Regeneron Pharmaceuticals, Inc. 2 3

3 Coronary Heart Disease Arteriosclerotic Heart Disease With Angina I25.10 Atherosclerotic heart disease of native coronary artery without angina pectoris I Atherosclerotic heart disease of native coronary artery with unstable angina pectoris I Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm I Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris I Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris I Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris I Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm I Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris I Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris I Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris I Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm I Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris I Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris I Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris I Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm I Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris I Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris I Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris I Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm I Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris I Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris I Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris I Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm I Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris I Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris I Atherosclerosis of coronary artery bypass graft(s) without angina pectoris I Atherosclerosis of native coronary artery of transplanted heart with unstable angina I Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm I Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris I Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris I Atherosclerosis of native coronary artery of transplanted heart without angina pectoris I Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina I Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm I Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris I Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris I Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris Arteriosclerotic Heart Disease (other) I25.82 Chronic total occlusion of coronary artery I25.83 Coronary atherosclerosis due to lipid rich plaque I25.84 Coronary atherosclerosis due to calcified coronary artery lesion Acute Coronary Syndromes I24.1 Dressler s syndrome (postmyocardial infarction syndrome) I24.0 Acute coronary thrombosis not resulting in myocardial infarction I24.8 Other forms of acute ischemic heart disease (includes acute and subacute coronary insufficiency) I23.7 Postinfarction angina Acute Myocardial Infarction (active) I21.09 ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall I21.01 ST elevation (STEMI) myocardial infarction involving left main coronary artery I21.02 ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery I22.0 Subsequent ST elevation (STEMI) myocardial infarction of anterior wall I21.19 ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall I22.1 Subsequent ST elevation (STEMI) myocardial infarction of inferior wall I21.11 ST elevation (STEMI) myocardial infarction involving right coronary artery I21.29 ST elevation (STEMI) myocardial infarction involving other sites I21.4 Non-ST elevation (NSTEMI) myocardial infarction I22.2 Subsequent non-st elevation (NSTEMI) myocardial infarction I21.21 ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery I22.8 Subsequent ST elevation (STEMI) myocardial infarction of other sites I21.3 ST elevation (STEMI) myocardial infarction of unspecified site I22.9 Subsequent ST elevation (STEMI) myocardial infarction of unspecified site History of Heart Attack (old) I25.2 Old myocardial infarction Coronary Revascularization Z95.1 Presence of aortocoronary bypass graft (assigned when the patient is status post CABG) Z95.5 Presence of coronary angioplasty implant and graft (assigned when the patient is status post coronary artery angioplasty with stenting) Z98.61 Coronary angioplasty status (assigned when the patient is status post coronary artery angioplasty without stenting) PRALUENT (alirocumab) is contraindicated in patients with a history of a serious hypersensitivity reaction to PRALUENT. Reactions have included hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization. 4 5

4 Cerebrovascular Conditions Arteriosclerotic Cerebrovascular Disease I65.1 Occlusion and stenosis of basilar artery (not resulting in cerebral infarction) I65.21 Occlusion and stenosis of right carotid artery (not resulting in cerebral infarction) I65.22 Occlusion and stenosis of left carotid artery (not resulting in cerebral infarction) I65.23 Occlusion and stenosis of bilateral carotid arteries (not resulting in cerebral infarction) I65.29 Occlusion and stenosis of unspecified carotid artery (not resulting in cerebral infarction) I65.01 Occlusion and stenosis of right vertebral artery (not resulting in cerebral infarction) I65.02 Occlusion and stenosis of left vertebral artery (not resulting in cerebral infarction) I65.03 Occlusion and stenosis of bilateral vertebral arteries (not resulting in cerebral infarction) I65.09 Occlusion and stenosis of unspecified vertebral artery (not resulting in cerebral infarction) I65.8 Occlusion and stenosis of other precerebral arteries (not resulting in cerebral infarction) I65.9 Occlusion and stenosis of unspecified precerebral artery (not resulting in cerebral infarction) I66.01 Occlusion and stenosis of right middle cerebral artery (not resulting in cerebral infarction) I66.02 Occlusion and stenosis of left middle cerebral artery (not resulting in cerebral infarction) I66.03 Occlusion and stenosis of bilateral middle cerebral arteries (not resulting in cerebral infarction) I66.09 Occlusion and stenosis of unspecified middle cerebral artery (not resulting in cerebral infarction) I66.11 Occlusion and stenosis of right anterior cerebral artery (not resulting in cerebral infarction) I66.12 Occlusion and stenosis of left anterior cerebral artery (not resulting in cerebral infarction) I66.13 Occlusion and stenosis of bilateral anterior cerebral arteries (not resulting in cerebral infarction) I66.19 Occlusion and stenosis of unspecified anterior cerebral artery (not resulting in cerebral infarction) I66.21 Occlusion and stenosis of right posterior cerebral artery (not resulting in cerebral infarction) I66.22 Occlusion and stenosis of left posterior cerebral artery (not resulting in cerebral infarction) I66.23 Occlusion and stenosis of bilateral posterior cerebral arteries (not resulting in cerebral infarction) I66.29 Occlusion and stenosis of unspecified posterior cerebral artery (not resulting in cerebral infarction) I66.3 Occlusion and stenosis of cerebellar arteries (not resulting in cerebral infarction) I66.8 Occlusion and stenosis of other cerebral arteries (not resulting in cerebral infarction) I66.9 Occlusion and stenosis of unspecified cerebral artery (not resulting in cerebral infarction) I67.2 Cerebral atherosclerosis (not resulting in cerebral infarction) I67.81 Acute cerebrovascular insufficiency (not resulting in cerebral infarction) I67.82 Cerebral ischemia (not resulting in cerebral infarction) Ischemic Stroke I63.02 Cerebral infarction due to thrombosis of basilar artery I63.12 Cerebral infarction due to embolism of basilar artery I63.22 Cerebral infarction due to unspecified occlusion or stenosis of basilar arteries I Cerebral infarction due to thrombosis of right carotid artery I Cerebral infarction due to thrombosis of left carotid artery I Cerebral infarction due to thrombosis of unspecified carotid artery I Cerebral infarction due to embolism of right carotid artery I Cerebral infarction due to embolism of left carotid artery I Cerebral infarction due to embolism of unspecified carotid artery I Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries I Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries I Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid arteries I Cerebral infarction due to thrombosis of right vertebral artery I Cerebral infarction due to thrombosis of left vertebral artery I Cerebral infarction due to thrombosis of unspecified vertebral artery I Cerebral infarction due to embolism of right vertebral artery I Cerebral infarction due to embolism of left vertebral artery I Cerebral infarction due to embolism of unspecified vertebral artery I Cerebral infarction due to unspecified occlusion or stenosis of right vertebral arteries I Cerebral infarction due to unspecified occlusion or stenosis of left vertebral arteries I Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral arteries I63.09 Cerebral infarction due to thrombosis of other precerebral artery I63.19 Cerebral infarction due to embolism of other precerebral artery I63.29 Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries I63.00 Cerebral infarction due to thrombosis of unspecified precerebral artery I63.10 Cerebral infarction due to embolism of unspecified precerebral artery I63.20 Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries Hypersensitivity reactions (e.g., pruritus, rash, urticaria), including some serious events (e.g., hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization), have been reported with PRALUENT treatment. If signs or symptoms of serious allergic reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve. 6 7

5 Ischemic Stroke (cont d) I63.30 Cerebral infarction due to thrombosis of unspecified cerebral artery I Cerebral infarction due to thrombosis of right middle cerebral artery I Cerebral infarction due to thrombosis of left middle cerebral artery I Cerebral infarction due to thrombosis of unspecified middle cerebral artery I Cerebral infarction due to thrombosis of right anterior cerebral artery I Cerebral infarction due to thrombosis of left anterior cerebral artery I Cerebral infarction due to thrombosis of unspecified anterior cerebral artery I Cerebral infarction due to thrombosis of right posterior cerebral artery I Cerebral infarction due to thrombosis of left posterior cerebral artery I Cerebral infarction due to thrombosis of unspecified posterior cerebral artery I Cerebral infarction due to thrombosis of right cerebellar artery I Cerebral infarction due to thrombosis of left cerebellar artery I Cerebral infarction due to thrombosis of unspecified cerebellar artery I63.39 Cerebral infarction due to thrombosis of other cerebral artery I63.6 Cerebral infarction due to cerebral venous thrombosis, nonpyogenic I63.40 Cerebral infarction due to embolism of unspecified cerebral artery I Cerebral infarction due to embolism of right middle cerebral artery I Cerebral infarction due to embolism of left middle cerebral artery I Cerebral infarction due to embolism of unspecified middle cerebral artery I Cerebral infarction due to embolism of right anterior cerebral artery I Cerebral infarction due to embolism of left anterior cerebral artery I Cerebral infarction due to embolism of unspecified anterior cerebral artery I Cerebral infarction due to embolism of right posterior cerebral artery I Cerebral infarction due to embolism of left posterior cerebral artery I Cerebral infarction due to embolism of unspecified posterior cerebral artery I Cerebral infarction due to embolism of right cerebellar artery I Cerebral infarction due to embolism of left cerebellar artery I Cerebral infarction due to embolism of unspecified cerebellar artery I63.49 Cerebral infarction due to embolism of other cerebral artery I63.50 Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery I Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery I Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery I Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery I Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery I Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery I Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery I Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery I Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery I Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery I Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery I Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar cerebral artery I Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery I63.59 Cerebral infarction due to unspecified occlusion or stenosis of other cerebral arteries I63.8 Other cerebral infarction I63.9 Cerebral infarction, unspecified Transient Ischemic Attack (TIA) G45.0 Vertebro-basilar artery syndrome G45.1 Carotid artery syndrome (hemispheric) G45.2 Multiple and bilateral precerebral artery syndromes G45.8 Other transient cerebral ischemic attacks and related syndromes G45.9 Transient cerebral ischemic attack, unspecified The most commonly occurring adverse reactions ( 5% of patients treated with PRALUENT and occurring more frequently than with placebo) are nasopharyngitis, injection site reactions, and influenza. 8 9

6 History of Ischemic Stroke With Residuals I69.31 Cognitive deficits following cerebral infarction I Aphasia following cerebral infarction I Dysphasia following cerebral infarction I Dysarthria following cerebral infarction I Fluency disorder following cerebral infarction I Other speech and language deficits following cerebral infarction I Hemiplegia and hemiparesis following cerebral infarction affecting unspecified side I Hemiplegia and hemiparesis following cerebral infarction affecting right dominant side I Hemiplegia and hemiparesis following cerebral infarction affecting left dominant side I Hemiplegia and hemiparesis following cerebral infarction affecting right non-dominant side I Hemiplegia and hemiparesis following cerebral infarction affecting left non-dominant side I Monoplegia of upper limb following cerebral infarction affecting unspecified side I Monoplegia of upper limb following cerebral infarction affecting right dominant side I Monoplegia of upper limb following cerebral infarction affecting left dominant side I Monoplegia of upper limb following cerebral infarction affecting right non-dominant side I Monoplegia of upper limb following cerebral infarction affecting left non-dominant side I Monoplegia of lower limb following cerebral infarction affecting unspecified side I Monoplegia of lower limb following cerebral infarction affecting right dominant side I Monoplegia of lower limb following cerebral infarction affecting left dominant side I Monoplegia of lower limb following cerebral infarction affecting right non-dominant side I Monoplegia of lower limb following cerebral infarction affecting left non-dominant side I Other paralytic syndrome following cerebral infarction affecting unspecified side I Other paralytic syndrome following cerebral infarction affecting right dominant side I Other paralytic syndrome following cerebral infarction affecting left dominant side I Other paralytic syndrome following cerebral infarction affecting right non-dominant side I Other paralytic syndrome following cerebral infarction affecting left non-dominant side I Other paralytic syndrome following cerebral infarction, bilateral I Other sequelae of cerebral infarction I Apraxia following cerebral infarction I Dysphagia following cerebral infarction I Facial weakness following cerebral infarction I Ataxia following cerebral infarction I Other sequelae of cerebral infarction I69.30 Unspecified sequelae of cerebral infarction Peripheral Vascular Conditions Atherosclerosis of Peripheral and Other Non-coronary, Non-cerebral Vessels I70.0 Atherosclerosis of aorta I70.1 Atherosclerosis of renal artery I Unspecified atherosclerosis of native arteries of extremities, right leg I Unspecified atherosclerosis of native arteries of extremities, left leg I Unspecified atherosclerosis of native arteries of extremities, bilateral legs I Unspecified atherosclerosis of native arteries of extremities, other extremity I Unspecified atherosclerosis of native arteries of extremities, unspecified extremity I Atherosclerosis of native arteries of extremities with intermittent claudication, right leg I Atherosclerosis of native arteries of extremities with intermittent claudication, left leg I Atherosclerosis of native arteries of extremities with intermittent claudication, bilateral legs I Atherosclerosis of native arteries of extremities with intermittent claudication, other extremity I Atherosclerosis of native arteries of extremities with intermittent claudication, unspecified extremity I Atherosclerosis of native arteries of extremities with rest pain, right leg I Atherosclerosis of native arteries of extremities with rest pain, left leg I Atherosclerosis of native arteries of extremities with rest pain, bilateral legs I Atherosclerosis of native arteries of extremities with rest pain, other extremity I Atherosclerosis of native arteries of extremities with rest pain, unspecified extremity Local injection site reactions including erythema/redness, itching, swelling, and pain/tenderness were reported more frequently in patients treated with PRALUENT (7.2% versus 5.1% for PRALUENT and placebo, respectively). Few patients discontinued treatment because of these reactions (0.2% versus 0.4% for PRALUENT and placebo, respectively), but patients receiving PRALUENT had a greater number of injection site reactions, had more reports of associated symptoms, and had reactions of longer average duration than patients receiving placebo. History of TIA or Stroke Without Residuals Z86.73 Personal history of transient ischemic attack (TIA) and cerebral infarction without residual deficits 10 11

7 Atherosclerosis of Peripheral and Other Non-coronary, Non-cerebral Vessels (cont d) I Atherosclerosis of native arteries of right leg with ulceration of thigh I Atherosclerosis of native arteries of right leg with ulceration of calf I Atherosclerosis of native arteries of right leg with ulceration of ankle I Atherosclerosis of native arteries of right leg with ulceration of heel and midfoot I Atherosclerosis of native arteries of right leg with ulceration of other part of foot I Atherosclerosis of native arteries of right leg with ulceration of other part of lower right leg I Atherosclerosis of native arteries of right leg with ulceration of unspecified site I Atherosclerosis of native arteries of left leg with ulceration of thigh I Atherosclerosis of native arteries of left leg with ulceration of calf I Atherosclerosis of native arteries of left leg with ulceration of ankle I Atherosclerosis of native arteries of left leg with ulceration of heel and midfoot I Atherosclerosis of native arteries of left leg with ulceration of other part of foot I Atherosclerosis of native arteries of left leg with ulceration of other part of lower left leg I Atherosclerosis of native arteries of left leg with ulceration of unspecified site I70.25 Atherosclerosis of native arteries of other extremities with ulceration I Atherosclerosis of native arteries of extremities with gangrene, right leg I Atherosclerosis of native arteries of extremities with gangrene, left leg I Atherosclerosis of native arteries of extremities with gangrene, bilateral legs I Atherosclerosis of native arteries of extremities with gangrene, other extremity I Atherosclerosis of native arteries of extremities with gangrene, unspecified extremity I Other atherosclerosis of native arteries of extremities, right leg I Other atherosclerosis of native arteries of extremities, left leg I Other atherosclerosis of native arteries of extremities, bilateral legs I Other atherosclerosis of native arteries of extremities, other extremity I Other atherosclerosis of native arteries of extremities, unspecified extremity Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, right leg I Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, left leg I Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, bilateral legs I Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, other extremity I Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, unspecified extremity I Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, right leg I Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, left leg I Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, bilateral legs I Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, other extremity I Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, unspecified extremity I Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, right leg I Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, left leg I Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, bilateral legs I Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, other extremity I Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, unspecified extremity I Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of thigh I Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of calf I Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of ankle I Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of heel and midfoot I Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of other part of foot I Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of other part of lower leg I Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of unspecified site I Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of thigh I Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of calf I Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of ankle I Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of heel and midfoot I Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of other part of foot I Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of other part of lower leg I Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of unspecified site I70.35 Atherosclerosis, unspecified type of bypass graft of other extremity, with ulceration I Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, right leg I Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, left leg I Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, bilateral legs I Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, other extremity I Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, unspecified extremity I Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, right leg I Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, left leg I Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, bilateral legs I Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, other extremity I Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, unspecified extremity Neurocognitive events were reported in 0.8% of patients treated with PRALUENT and 0.7% of patients treated with placebo. Confusion or memory impairment were reported more frequently by those treated with PRALUENT (0.2% for each) than in those treated with placebo (<0.1% for each)

8 Atherosclerosis of Peripheral and Other Non-coronary, Non-cerebral Vessels (cont d) I Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, right leg I Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, left leg I Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, bilateral legs I Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, other extremity I Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, unspecified extremity I Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, right leg I Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, left leg I Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, bilateral legs I Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, other extremity I Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, unspecified extremity I Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, right leg I Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, left leg I Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, bilateral legs I Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, other extremity I Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, unspecified extremity I Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of thigh I Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of calf I Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of ankle I Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of heel and midfoot I Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of other part of foot I Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of other part of lower leg I Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of unspecified site I Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of thigh I Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of calf I Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of ankle I Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of heel and midfoot I Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of other part of foot I Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of other part of lower leg I Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of unspecified site I70.65 Atherosclerosis of nonbiological bypass graft(s) of other extremity with ulceration I Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, right leg I Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, left leg I Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, bilateral legs I Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, other extremity I Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, unspecified extremity I Other atherosclerosis of nonbiological bypass graft(s) of the extremities, right leg I Other atherosclerosis of nonbiological bypass graft(s) of the extremities, left leg I Other atherosclerosis of nonbiological bypass graft(s) of the extremities, bilateral legs I Other atherosclerosis of nonbiological bypass graft(s) of the extremities, other extremity I Other atherosclerosis of nonbiological bypass graft(s) of the extremities, unspecified extremity I Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, right leg I Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, left leg I Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, bilateral legs I Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, other extremity I Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, unspecified extremity I Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, right leg I Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, left leg I Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, bilateral legs I Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, other extremity I Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, unspecified extremity I Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, right leg I Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, left leg I Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, bilateral legs I Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, other extremity I Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, unspecified extremity I Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of thigh I Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of calf I Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of ankle I Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of heel and midfoot I Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of other part of foot I Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of other part of lower leg I Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of unspecified site Liver-related disorders (primarily related to abnormalities in liver enzymes) were reported in 2.5% of patients treated with PRALUENT and 1.8% of patients treated with placebo, leading to treatment discontinuation in 0.4% and 0.2% of patients, respectively. Increases in serum transaminases to greater than 3 times the upper limit of normal occurred in 1.7% of patients treated with PRALUENT and 1.4% of patients treated with placebo

9 Atherosclerosis of Peripheral and Other Non-coronary, Non-cerebral Vessels (cont d) I Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of thigh I Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of calf I Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of ankle I Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of heel and midfoot I Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of other part of foot I Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of other part of lower leg I Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of unspecified site I70.75 Atherosclerosis of other type of bypass graft(s) of other extremity with ulceration I Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, right leg I Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, left leg I Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, bilateral legs I Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, other extremity I Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, unspecified extremity I Other atherosclerosis of other type of bypass graft(s) of the extremities, right leg I Other atherosclerosis of other type of bypass graft(s) of the extremities, left leg I Other atherosclerosis of other type of bypass graft(s) of the extremities, bilateral legs I Other atherosclerosis of other type of bypass graft(s) of the extremities, other extremity I Other atherosclerosis of other type of bypass graft(s) of the extremities, unspecified extremity I Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, right leg I Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, left leg I Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, bilateral legs I Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, other extremity I Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, unspecified extremity I Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, right leg I Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, left leg I Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, bilateral legs I Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, other extremity I Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, unspecified extremity I Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, right leg I Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, left leg I Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, bilateral legs I Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, other extremity I Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, unspecified extremity I Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of thigh I Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of calf I Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of ankle I Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of heel and midfoot I Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of other part of foot I Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of other part of lower leg I Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of unspecified site I Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of thigh I Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of calf I Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of ankle I Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of heel and midfoot I Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of other part of foot I Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of other part of lower leg I Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of unspecified site I70.45 Atherosclerosis of autologous vein bypass graft(s) of other extremity with ulceration I Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, right leg I Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, left leg I Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, bilateral legs I Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, other extremity I Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, unspecified extremity I Other atherosclerosis of autologous vein bypass graft(s) of the extremities, right leg I Other atherosclerosis of autologous vein bypass graft(s) of the extremities, left leg I Other atherosclerosis of autologous vein bypass graft(s) of the extremities, bilateral legs I Other atherosclerosis of autologous vein bypass graft(s) of the extremities, other extremity I Other atherosclerosis of autologous vein bypass graft(s) of the extremities, unspecified extremity The most common adverse reactions leading to treatment discontinuation in patients treated with PRALUENT were allergic reactions (0.6% versus 0.2% for PRALUENT and placebo, respectively) and elevated liver enzymes (0.3% versus <0.1%). PRALUENT is a human monoclonal antibody. As with all therapeutic proteins, there is a potential for immunogenicity with PRALUENT

10 Atherosclerosis of Peripheral and Other Non-coronary, Non-cerebral Vessels (cont d) I Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, right leg I Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, left leg I Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, bilateral legs I Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, other extremity I Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, unspecified extremity I Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, right leg I Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, left leg I Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, bilateral legs I Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, other extremity I Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, unspecified extremity I Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, right leg I Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, left leg I Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, bilateral legs I Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, other extremity I Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, unspecified extremity I Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of thigh I Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of calf I Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of ankle I Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of heel and midfoot I Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of other part of foot I Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of other part of lower leg I Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of unspecified site I Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of thigh I Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of calf I Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of ankle I Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of heel and midfoot I Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of other part of foot I Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of other part of lower leg I Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of unspecified site I70.55 Atherosclerosis of nonautologous biological bypass graft(s) of other extremity with ulceration I Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, right leg I Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, left leg I Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, bilateral legs I Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, other extremity I Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, unspecified extremity I Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, right leg I Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, left leg I Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, bilateral legs I Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, other extremity I Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, unspecified extremity I70.8 Atherosclerosis of other arteries I70.90 Unspecified atherosclerosis I70.91 Generalized atherosclerosis I70.92 Chronic total occlusion of artery of extremities I73.9 Peripheral vascular disease, unspecified (assigned for PVD and PAD) Peripheral Artery Revascularization Z Peripheral vascular angioplasty status with implants and grafts (assigned when the patient is status post peripheral artery angioplasty with stenting) Z98.62 Peripheral vascular angioplasty status (assigned when the patient is status post peripheral artery angioplasty without stenting) PRALUENT (alirocumab) is contraindicated in patients with a history of a serious hypersensitivity reaction to PRALUENT. Reactions have included hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization

11 Frequently Used Codes For My Office Notes Use this section to keep track of the ICD-10 diagnosis codes that your office frequently uses when prescribing PRALUENT (alirocumab) or enrolling patients in MyPRALUENT. ICD-10 Diagnosis Code Code Description Hypersensitivity reactions (e.g., pruritus, rash, urticaria), including some serious events (e.g., hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization), have been reported with PRALUENT treatment. If signs or symptoms of serious allergic reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve

12 Important Safety Information PRALUENT (alirocumab) is contraindicated in patients with a history of a serious hypersensitivity reaction to PRALUENT. Reactions have included hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization. Hypersensitivity reactions (e.g., pruritus, rash, urticaria), including some serious events (e.g., hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization), have been reported with PRALUENT treatment. If signs or symptoms of serious allergic reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve. The most commonly occurring adverse reactions ( 5% of patients treated with PRALUENT and occurring more frequently than with placebo) are nasopharyngitis, injection site reactions, and influenza. Local injection site reactions including erythema/redness, itching, swelling, and pain/tenderness were reported more frequently in patients treated with PRALUENT (7.2% versus 5.1% for PRALUENT and placebo, respectively). Few patients discontinued treatment because of these reactions (0.2% versus 0.4% for PRALUENT and placebo, respectively), but patients receiving PRALUENT had a greater number of injection site reactions, had more reports of associated symptoms, and had reactions of longer average duration than patients receiving placebo. Neurocognitive events were reported in 0.8% of patients treated with PRALUENT and 0.7% of patients treated with placebo. Confusion or memory impairment were reported more frequently by those treated with PRALUENT (0.2% for each) than in those treated with placebo (<0.1% for each). Liver-related disorders (primarily related to abnormalities in liver enzymes) were reported in 2.5% of patients treated with PRALUENT and 1.8% of patients treated with placebo, leading to treatment discontinuation in 0.4% and 0.2% of patients, respectively. Increases in serum transaminases to greater than 3 times the upper limit of normal occurred in 1.7% of patients treated with PRALUENT and 1.4% of patients treated with placebo. The most common adverse reactions leading to treatment discontinuation in patients treated with PRALUENT were allergic reactions (0.6% versus 0.2% for PRALUENT and placebo, respectively) and elevated liver enzymes (0.3% versus <0.1%). PRALUENT is a human monoclonal antibody. As with all therapeutic proteins, there is a potential for immunogenicity with PRALUENT. If you have questions about ICD-10 or need more information, call a MyPRALUENT care specialist at PRALUENT ( ) or contact your field access specialist

CHAPTER 9 DISEASES OF THE CIRCULATORY SYSTEM (I00-I99)

CHAPTER 9 DISEASES OF THE CIRCULATORY SYSTEM (I00-I99) CHAPTER 9 DISEASES OF THE CIRCULATORY SYSTEM (I00-I99) March 2014 2014 MVP Health Care, Inc. CHAPTER 9 CHAPTER SPECIFIC CATEGORY CODE BLOCKS I00-I02 Acute rheumatic fever I05-I09 Chronic rheumatic heart

More information

Homocysteine Level. Test Code Test Name CPT. HCYS Homocysteine Level 83090

Homocysteine Level. Test Code Test Name CPT. HCYS Homocysteine Level 83090 Test Code Test Name CPT HCYS Homocysteine Level 83090 Page 1 of 4 Narrative Description ICD9 Acute Coronary Occlusion without Myocardial Infarction 411.81 Acute Myocardial Infarction of Anterolateral Wall

More information

APPENDIX A NEUROLOGIST S GUIDE TO USING ICD-9-CM CODES FOR CEREBROVASCULAR DISEASES INTRODUCTION

APPENDIX A NEUROLOGIST S GUIDE TO USING ICD-9-CM CODES FOR CEREBROVASCULAR DISEASES INTRODUCTION APPENDIX A NEUROLOGIST S GUIDE TO USING ICD-9-CM CODES FOR CEREBROVASCULAR DISEASES INTRODUCTION ICD-9-CM codes for cerebrovascular diseases is not user friendly. This presentation is designed to assist

More information

Adult Cardiac Surgery ICD9 to ICD10 Crosswalks

Adult Cardiac Surgery ICD9 to ICD10 Crosswalks 164.1 Malignant neoplasm of heart C38.0 Malignant neoplasm of heart 164.1 Malignant neoplasm of heart C45.2 Mesothelioma of pericardium 198.89 Secondary malignant neoplasm of other specified sites C79.89

More information

NCD for Lipids Testing

NCD for Lipids Testing Applicable CPT Code(s): NCD for Lipids Testing 80061 Lipid panel 82465 Cholesterol, serum or whole blood, total 83700 Lipoprotein, blood; electrophoretic separation and quantitation 83701 Lipoprotein blood;

More information

LIPID PANEL CHOLESTEROL LIPOPROTEIN, ELECTROPHORETIC SEPARATION LIPOPROTEIN, DIRECT MEASUREMENT (HDL) LDL DIRECT TRIGLYCERIDES

LIPID PANEL CHOLESTEROL LIPOPROTEIN, ELECTROPHORETIC SEPARATION LIPOPROTEIN, DIRECT MEASUREMENT (HDL) LDL DIRECT TRIGLYCERIDES Test Code Test Name CPT CHOL Cholesterol, Serum 82465 HDL HDL, (High Density Lipoprotein) 83718 TRIG Triglycerides, Serum 84478 FTRIG Triglycerides (Fluid) 84478 LIPID Lipid Panel 80061 LDL LDL (Low Density

More information

ICD-10 Dx Edit Code Lists

ICD-10 Dx Edit Code Lists Integrated Outpatient Code Editor Software ICD-10 Dx Edit Code Lists v15.0 ICD-10 Pilot 3M Health Information Systems 100 Barnes Road Wallingford, CT 06492 CPT codes, descriptions and material only are

More information

E08.621 Diabetes mellitus due to underlying condition with foot ulcer E09.621 Drug or chemical induced diabetes mellitus with foot ulcer E10.10 Type 1 diabetes mellitus with ketoacidosis without coma E10.11

More information

Diagnosis Code Crosswalk : ICD-9-CM to ICD-10-CM Cardiac Rhythm and Heart Failure Diagnoses

Diagnosis Code Crosswalk : ICD-9-CM to ICD-10-CM Cardiac Rhythm and Heart Failure Diagnoses Diagnosis Code Crosswalk : to 402.01 Hypertensive heart disease, malignant, with heart failure 402.11 Hypertensive heart disease, benign, with heart failure 402.91 Hypertensive heart disease, unspecified,

More information

Long term care coding issues for ICD-10-CM

Long term care coding issues for ICD-10-CM Long term care coding issues for ICD-10-CM Coding Clinic, Fourth Quarter 2012 Pages: 90-98 Effective with discharges: October 1, 2012 Related Information Long Term Care Coding Issues for ICD-10-CM Coding

More information

Speaking ICD-10-CM. The New Coding Language. COPD documented with a more specific respiratory condition falls under one code category: J44.0-J44.

Speaking ICD-10-CM. The New Coding Language. COPD documented with a more specific respiratory condition falls under one code category: J44.0-J44. Speaking : Chronic Obstructive Pulmonary Disease (COPD) COPD documented with a more specific respiratory condition falls under multiple code categories: 491.20-491.22 Obstructive chronic bronchitis 493.20-493.22

More information

CARDIA 288 MONTH FOLLOW-UP SUPPLEMENTAL FORM (FORM B) HOSPITALIZATION CASE #: INTERVIEWER ID FY288BIVID2. Page 1 of 6 FY288BH4CN

CARDIA 288 MONTH FOLLOW-UP SUPPLEMENTAL FORM (FORM B) HOSPITALIZATION CASE #: INTERVIEWER ID FY288BIVID2. Page 1 of 6 FY288BH4CN HOSPITALIZATION CASE #: 2 8 8 0 H FY288BH4CN Has the participant indicated any of the following reasons for being admitted overnight for this case? 1. Suspected or confirmed problems with the heart, circulation,

More information

Vertebrobasilar Disease

Vertebrobasilar Disease The Vascular Surgery team at the University of Michigan is dedicated to providing exceptional treatments for in the U-M Cardiovascular Center (CVC), our new state-of-the-art clinical facility. Treatment

More information

Risk Adjustment Coding/Documentation Checklist

Risk Adjustment Coding/Documentation Checklist Risk Adjustment Coding/Documentation Checklist The following list should be used to ensure that all member and diagnosis-related information is reported, and all the member s chronic conditions are documented

More information

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations.

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. INTRODUCTION Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. Although decrease in cardiovascular mortality still major cause of morbidity & burden of disease.

More information

Physical and Occupational Therapy Tip Sheet for ICD-10

Physical and Occupational Therapy Tip Sheet for ICD-10 Physical and Occupational Therapy Tip Sheet for ICD-10 Bursitis or Tendinitis Carpal Tunnel Syndrome Document specific site: (e.g. hand, knee, prepatellar, hip, shoulder, etc.) Cervicalgia Document the

More information

MEDICAL POLICY No. 91580-R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE

MEDICAL POLICY No. 91580-R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE Effective Date: October 1, 2015 Review Dates: 10/11, 10/12, 10/13, 8/14, 8/15 Date Of Origin: October 12, 2011 Status: Current Summary of Changes Clarifications:

More information

Rehabilitation Best Practice Documentation

Rehabilitation Best Practice Documentation Rehabilitation Best Practice Documentation Click on the desired Diagnoses link or press Enter to view all information. Diagnoses: Reason for Admission to Inpatient Rehab CVA Deficits Fractures Secondary

More information

Subclavian Steal Syndrome By Marta Thorup

Subclavian Steal Syndrome By Marta Thorup Subclavian Steal Syndrome By Marta Thorup Definition Subclavian steal syndrome (SSS), is a constellation of signs and symptoms that arise from retrograde flow of blood in the vertebral artery, due to proximal

More information

Stroke Coding Issues Presentation to: NorthEast Cerebrovascular Consortium

Stroke Coding Issues Presentation to: NorthEast Cerebrovascular Consortium Stroke Coding Issues Presentation to: NorthEast Cerebrovascular Consortium October 30, 2008 Barry Libman, RHIA, CCS, CCS-P President, Barry Libman Inc. Stroke Coding Issues Outline Medical record documentation

More information

Hospital-based SNF Coding Tip Sheet: Top 25 codes and ICD-10 Chapter Overview

Hospital-based SNF Coding Tip Sheet: Top 25 codes and ICD-10 Chapter Overview Hospital-based SNF Coding Tip Sheet: Top 25 codes and Chapter Overview Chapter 5 - Mental, Behavioral and Neurodevelopmental Disorders (F00-F99) Classification improvements (different categories) expansions:

More information

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease PRECOMBAT Trial Seung-Whan Lee, MD, PhD On behalf

More information

Automatic External Defibrillators

Automatic External Defibrillators Last Review Date: May 27, 2016 Number: MG.MM.DM.10dC2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth

More information

Day Rehab ICD-10 documentation

Day Rehab ICD-10 documentation Day Rehab documentation Seven key impacts to documentation 1. Disease or disorder site 2. Acuity and/or encounter status of treatment 3. Etiology, causative agent, or disease type and injury/ poisoning

More information

Deciphering Cardiovascular Disease in ICD-10

Deciphering Cardiovascular Disease in ICD-10 7th Annual Association for Clinical Documentation Improvement Specialists Conference Deciphering Cardiovascular Disease in ICD-10 James P. Fee, MD, CCS, CCDS, AHIMA-Approved ICD-10-CM/PCS Trainer Associate

More information

Coding in Germany - The Use of ICD-10 for Diagnoses

Coding in Germany - The Use of ICD-10 for Diagnoses Coding in Germany - The Use of ICD-10 for Diagnoses Dr. Thomas Mansky, TU Berlin Th. Mansky, HIMSS 2012 1 DISCLAIMER: The views and opinions expressed in this presentation are those of the author and do

More information

Cardiac Rehabilitation CARDIAC REHABILITATION HS-091. Policy Number: HS-091. Original Effective Date: 3/16/2009

Cardiac Rehabilitation CARDIAC REHABILITATION HS-091. Policy Number: HS-091. Original Effective Date: 3/16/2009 Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. M issouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,

More information

DIAGNOSTIC CRITERIA OF STROKE

DIAGNOSTIC CRITERIA OF STROKE DIAGNOSTIC CRITERIA OF STROKE Diagnostic criteria are used to validate clinical diagnoses. Here below MONICA diagnostic criteria are reported. MONICA - MONItoring trends and determinants of CArdiovascular

More information

Not Cardio - Vascular Coding. Caren J Swartz, CPC-I, CPC-H, CPMA

Not Cardio - Vascular Coding. Caren J Swartz, CPC-I, CPC-H, CPMA Not Cardio - Vascular Coding Caren J Swartz, CPC-I, CPC-H, CPMA caren@practiceintegrity.com Objectives Understand Anatomy for Vascular Coding Review the Rules for Vascular Procedures Review ICD-10 future

More information

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38 Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac

More information

Ischemia and Infarction

Ischemia and Infarction Harvard-MIT Division of Health Sciences and Technology HST.035: Principle and Practice of Human Pathology Dr. Badizadegan Ischemia and Infarction HST.035 Spring 2003 In the US: ~50% of deaths are due to

More information

ICD-10 CM Training. Cardiology

ICD-10 CM Training. Cardiology ICD-10 CM Training Cardiology ICD-10-CM Compliance Dates ICD-10-CM will be valid for dates of service on or after October 1, 2015 Outpatient dates of service of October 1, 2015 and beyond. Inpatient hospital

More information

WHY DO MY LEGS HURT? Veins, arteries, and other stuff.

WHY DO MY LEGS HURT? Veins, arteries, and other stuff. WHY DO MY LEGS HURT? Veins, arteries, and other stuff. Karl A. Illig, MD Professor of Surgery Chief, Division of Vascular Surgery Mitzi Ekers, ARNP April 2013 Why do my legs hurt? CONFLICTS OF INTEREST

More information

LCD L32559 - Lipid Profile/Cholesterol Testing Print

LCD L32559 - Lipid Profile/Cholesterol Testing Print Contractor Information LCD L32559 - Lipid Profile/Cholesterol Testing Print Contractor Name: Novitas Solutions, Inc. Contractor Number(s): 12501, 12101, 12102, 12201, 12202, 12301, 12302, 12401, 12402,

More information

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Local Coverage Determination (LCD): Cardiovascular Stress Testing, Including Exercise and/or Pharmacological Stress and Stress Echocardiography (L34324) Links in PDF documents are not guaranteed to work.

More information

190.23 Lipid Testing CPT Code : 80061 82465 83715 83716 83721 84478 Frequency Limitation Medicare National Coverage Determination Policy

190.23 Lipid Testing CPT Code : 80061 82465 83715 83716 83721 84478 Frequency Limitation Medicare National Coverage Determination Policy 190.23 Lipid Testing CPT Code : 80061 82465 83715 83716 83721 84478 Frequency Limitation Medicare National Coverage Determination Policy ICD10. I71.3 I71.4 R79.9 R93.3 R78.71 R79.0 R74.8 R74.9 L40.2 I67.81

More information

Neurology & Neurosurgery Tip Sheet for ICD-10

Neurology & Neurosurgery Tip Sheet for ICD-10 Alzheimer s Disease Attention Disder Document onset as: -Early -Late Document site, such as: - Predominantly inattentive - Predominantly hyperactive - Combined type If with dementia, document as: -With

More information

Local Coverage Article: NCD Coding Article for Positron Emission Tomography (PET) Scans Used for Non- Oncologic Conditions (A53134)

Local Coverage Article: NCD Coding Article for Positron Emission Tomography (PET) Scans Used for Non- Oncologic Conditions (A53134) Local Coverage Article: NCD Coding Article for Positron Emission Tomography (PET) Scans Used for Non- Oncologic Conditions (A53134) Contractor Information Contractor Name Novitas Solutions, Inc. Article

More information

Cancer and Heart/Stroke coverage

Cancer and Heart/Stroke coverage Cancer and Heart/Stroke coverage Assurant Supplemental Coverage» Pays cash right to you You never expect a life-threatening illness like cancer, heart attack or stroke. But if the unexpected happens to

More information

Cilostazol versus Clopidogrel after Coronary Stenting

Cilostazol versus Clopidogrel after Coronary Stenting Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background

More information

Process Representation #1 : The PAD algorithm as a sequential flow thru all sections

Process Representation #1 : The PAD algorithm as a sequential flow thru all sections Process Representation #1 : The PAD algorithm as a sequential flow thru all sections An exploded version of the above scoped section flow is shown below. Notes: The flow presupposes existing services (

More information

Preparing for ICD-10 for Physicians

Preparing for ICD-10 for Physicians Preparing for ICD-10 for Physicians May 2011 Notices These coding suggestions and coverage guidelines do not replace seeking coding advice from the payer and/or your coding staff. The ultimate responsibility

More information

Cardiovascular Endpoints

Cardiovascular Endpoints The Malmö Diet and Cancer Study Department of Clinical Sciences Malmö University Hospital Lund University The Malmö Diet and Cancer Study CV-cohort Cardiovascular Endpoints End of follow-up: 31 Dec * Report:

More information

LIMITED BENEFIT HEALTH COVERAGE FOR SPECIFIED CRITICAL ILLNESS. OUTLINE OF COVERAGE (Applicable to Policy Form CI-1.0-NC)

LIMITED BENEFIT HEALTH COVERAGE FOR SPECIFIED CRITICAL ILLNESS. OUTLINE OF COVERAGE (Applicable to Policy Form CI-1.0-NC) COLONIAL LIFE & ACCIDENT INSURANCE COMPANY 1200 Colonial Life Boulevard, P.O. Box 1365, Columbia, South Carolina 29202 1.800.325.4368 www.coloniallife.com A Stock Company LIMITED BENEFIT HEALTH COVERAGE

More information

Guidelines for Use of Clopidogrel (Plavix )

Guidelines for Use of Clopidogrel (Plavix ) East Lancashire Medicines Management Board representing East Lancashire Hospitals NHS Trust, Lancashire Care Trust, Blackburn with Darwen PCT, East Lancs PCT Licensed Indications Guidelines for Use of

More information

Acute Coronary Syndrome. What Every Healthcare Professional Needs To Know

Acute Coronary Syndrome. What Every Healthcare Professional Needs To Know Acute Coronary Syndrome What Every Healthcare Professional Needs To Know Background of ACS Acute Coronary Syndrome (ACS) is an umbrella term used to cover a spectrum of clinical conditions that are caused

More information

A Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs

A Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs A Patient s Guide to Primary and Secondary Prevention of PATIENT EDUCATION GUIDE What Is Cardiovascular Disease? Cardiovascular disease (CVD) is a broad term that covers any disease of the heart and circulatory

More information

--------------------DOSAGE FORMS AND STRENGTHS--------------------

--------------------DOSAGE FORMS AND STRENGTHS-------------------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PRALUENT safely and effectively. See full prescribing information for PRALUENT. PRALUENT TM (alirocumab)

More information

Making Sense of the New Statin guidelines. They are more than just lowering your cholesterol!

Making Sense of the New Statin guidelines. They are more than just lowering your cholesterol! Making Sense of the New Statin guidelines They are more than just lowering your cholesterol! No Disclosures Margaret (Peg) O Donnell DNPs, FNP, ANP B-C, FAANP Senior Nurse Practitioner South Nassau Communities

More information

Guidelines Most Significantly Affected Under ICD-10-CM. May 29, 2013

Guidelines Most Significantly Affected Under ICD-10-CM. May 29, 2013 Guidelines Most Significantly Affected Under ICD-10-CM May 29, 2013 Guidelines Most Significantly Affected Under ICD-10-CM A look at the new system and how it compares to ICD-9-CM Presented by Therese

More information

Malmö Preventive Project. Cardiovascular Endpoints

Malmö Preventive Project. Cardiovascular Endpoints Malmö Preventive Project Department of Clinical Sciences Malmö University Hospital Lund University Malmö Preventive Project Cardiovascular Endpoints End of follow-up: 31 Dec 2008 * Report: 21 June 2010

More information

Solitaire FR Revascularization Device CODING AND REIMBURSEMENT GUIDE REIMBURSEMENT SUPPORT HOTLINE 877.278.7482

Solitaire FR Revascularization Device CODING AND REIMBURSEMENT GUIDE REIMBURSEMENT SUPPORT HOTLINE 877.278.7482 Solitaire FR Revascularization Device TM CODING AND GUIDE INTRODUCTION: HOSPITAL INPATIENT CODING SOLITAIRE FR REVASCULARIZATION DEVICE DESCRIPTION The Solitaire FR revascularization device is a self-expanding

More information

Your Guide to Express Critical Illness Insurance Definitions

Your Guide to Express Critical Illness Insurance Definitions Your Guide to Express Critical Illness Insurance Definitions Your Guide to EXPRESS Critical Illness Insurance Definitions This guide to critical illness definitions will help you understand the illnesses

More information

Main Effect of Screening for Coronary Artery Disease Using CT

Main Effect of Screening for Coronary Artery Disease Using CT Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,

More information

Rita Shugart, RN, RVT, FSVU Shugart Consulting February 7, 2015

Rita Shugart, RN, RVT, FSVU Shugart Consulting February 7, 2015 Rita Shugart, RN, RVT, FSVU Shugart Consulting February 7, 2015 No Conflicts Attendees are encouraged to review the specific statutes, regulations, and other interpretive materials referred to in this

More information

Cancer and Heart/Stroke coverage

Cancer and Heart/Stroke coverage Cancer and Heart/Stroke coverage Assurant Supplemental Coverage» Pays cash right to you You never expect a life-threatening illness like cancer, heart attack or stroke. But if the unexpected happens to

More information

GENERAL HEART DISEASE KNOW THE FACTS

GENERAL HEART DISEASE KNOW THE FACTS GENERAL HEART DISEASE KNOW THE FACTS WHAT IS Heart disease is a broad term meaning any disease affecting the heart. It is commonly used to refer to coronary heart disease (CHD), a more specific term to

More information

Cardiology ICD-10-CM Coding Tip Sheet Overview of Key Chapter Updates for Cardiology

Cardiology ICD-10-CM Coding Tip Sheet Overview of Key Chapter Updates for Cardiology Cardiology ICD-10-CM Coding Tip Sheet Overview of Key Chapter Updates for Cardiology Chapter 4: Endocrine, Nutritional, and Metabolic Diseases (E00-E89) The diabetes mellitus codes are combination codes

More information

Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty

Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty Round Table: Antithrombotic therapy beyond ACS Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty M. Matsagkas, MD, PhD, EBSQ-Vasc Associate Professor

More information

3/2/2010 Post CABG R h e bili a i tat on Ahmed Elkerdany Professor o f oof C ardiac Cardiac Surgery Ain Shams University 1

3/2/2010 Post CABG R h e bili a i tat on Ahmed Elkerdany Professor o f oof C ardiac Cardiac Surgery Ain Shams University 1 Post CABG Rehabilitation i Ahmed Elkerdany Professor of Cardiac Surgery Ain Shams University 1 Definition Cardiac rehabilitation services are comprehensive, long-term programs involving : medical evaluation.

More information

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): January 27, 2015 Effective Date: April 1, 2015 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT

More information

Diabetes Mellitus and the Circulatory System

Diabetes Mellitus and the Circulatory System Diabetes Mellitus and the Circulatory System Tricia A. Twombly BSN RN HCS-D HCS-O COS-C CHCE AHIMA Approved ICD-10 CM Trainer AHIMA Ambassador Senior Director DecisionHealth Chief Executive Officer Board

More information

Antonio Colombo MD on behalf of the SECURITY Investigators

Antonio Colombo MD on behalf of the SECURITY Investigators Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy - The SECURITY Randomized Clinical Trial Antonio Colombo MD on behalf of the SECURITY

More information

ICD-9-CM coding for patients with Traumatic Brain Injury*

ICD-9-CM coding for patients with Traumatic Brain Injury* ICD-9-CM coding for patients with Traumatic Brain Injury* The diagnostic code for sequelae of traumatic brain injury is: 907.0 Late effect of intracranial injury without mention of skull fracture (Late

More information

190.16 - Partial Thromboplastin Time (PTT)

190.16 - Partial Thromboplastin Time (PTT) 190.16 - Partial Thromboplastin Time (PTT) Other Names/Abbreviations PTT Basic plasma coagulation function is readily assessed with a few simple laboratory tests: The Partial Thromboplastin Time (PTT),

More information

Documentation Strategies in an ICD-10 World

Documentation Strategies in an ICD-10 World Documentation Strategies in an ICD-10 World Providence Holy Cross Medical Center; Mission Hills, CA September 2, 2015 Andrew H. Dombro, MD Internist/Hospitalist; Denver, CO Regional Medical Director JA

More information

LCD L30256 - C-Reactive Protein High Sensitivity Testing (hscrp)

LCD L30256 - C-Reactive Protein High Sensitivity Testing (hscrp) LCD L30256 - C-Reactive Protein High Sensitivity Testing (hscrp) Contractor Information Contractor Name: Novitas Solutions, Inc. Contractor Number(s): 12501, 12101, 12102, 12201, 12202, 12301, 12302, 12401,

More information

Duration of Dual Antiplatelet Therapy After Coronary Stenting

Duration of Dual Antiplatelet Therapy After Coronary Stenting Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are

More information

Cardiovascular Endpoints

Cardiovascular Endpoints The Malmö Diet and Cancer Study Department of Clinical Sciences Skåne University Hospital, Malmö Lund University The Malmö Diet and Cancer Study CV-cohort Cardiovascular Endpoints End of follow-up: 30

More information

PHC4 35 Diseases, Procedures, and Medical Conditions for which Laboratory Data is Required Effective 10/1/2015

PHC4 35 Diseases, Procedures, and Medical Conditions for which Laboratory Data is Required Effective 10/1/2015 PHC4 35 Diseases, Procedures, and Medical Conditions for which Laboratory Data is Required Effective 10/1/2015 Laboratory data is to be submitted for discharges in the following conditions: 1. Heart Attack

More information

Understanding Vascular Disease. The Ohio State University Heart and Vascular Center

Understanding Vascular Disease. The Ohio State University Heart and Vascular Center Understanding Vascular Disease The Ohio State University Heart and Vascular Center What is Vascular Disease? The vascular system is the body s network of blood vessels. It includes the arteries, veins

More information

COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION

COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION European Medicines Agency London, 19 July 2007 Doc. Ref. EMEA/CHMP/EWP/311890/2007 COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR

More information

Cardiovascular diseases. pathology

Cardiovascular diseases. pathology Cardiovascular diseases pathology Atherosclerosis Vascular diseases A disease that results in arterial wall thickens as a result of build- up of fatty materials such cholesterol, resulting in acute and

More information

PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION

PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION Hull & East Riding Prescribing Committee PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION For guidance on Primary Prevention please see NICE guidance http://www.nice.org.uk/guidance/cg181

More information

Medtronic Cardiac Rhythm and Heart Failure ICD-10 Coding for Physicians

Medtronic Cardiac Rhythm and Heart Failure ICD-10 Coding for Physicians Medtronic Cardiac Rhythm and Heart Failure ICD-10 Coding for Physicians May 19, 2015 Disclaimer This presentation is intended for educational use. Any duplication is prohibited without written consent

More information

Your healthcare provider has ordered a Boston Heart Cardiac Risk Assessment

Your healthcare provider has ordered a Boston Heart Cardiac Risk Assessment Your healthcare provider has ordered a Boston Heart Cardiac Risk Assessment What does that mean for you? Your healthcare provider has determined that you may be at risk for cardiovascular disease (CVD).

More information

Malmö Preventive Project. Cardiovascular Endpoints

Malmö Preventive Project. Cardiovascular Endpoints Malmö Preventive Project Department of Clinical Sciences Skåne University Hospital, Malmö Lund University Malmö Preventive Project Cardiovascular Endpoints End of follow-up: 30 June 2009 Report: 7 October

More information

The Bioresorbable Vascular Stent Dr Albert Ko

The Bioresorbable Vascular Stent Dr Albert Ko The Bioresorbable Vascular Stent Dr Albert Ko Dr Albert Ko MB BS, FRACP, FCSANZ Interventional/General Cardiologist Ascot Cardiology Symposium 2013 Treatment Goals for Coronary Artery Disease Relieve of

More information

ICD-9-CM coding for patients with Spinal Cord Injury*

ICD-9-CM coding for patients with Spinal Cord Injury* ICD-9-CM coding for patients with Spinal Cord Injury* indicates intervening codes have been left out of this list. OTHER DISORDERS OF THE CENTRAL NERVOUS SYSTEM (340-349) 344 Other paralytic syndromes

More information

ROYAL HOSPITAL FOR WOMEN

ROYAL HOSPITAL FOR WOMEN Therapeutic & Drug Utilisation Commmittee 20/4/10 INTRODUCTION Heparin prevents the conversion of prothrombin to thrombin and fibrinogen by increasing the activity of antithrombin III. This action prevents

More information

EXHIBIT H SETTLEMENT ELIGIBILITY CRITERIA. a) pharmacy records reflecting the dispensing of Bextra and/or Celebrex to the Class Member; or

EXHIBIT H SETTLEMENT ELIGIBILITY CRITERIA. a) pharmacy records reflecting the dispensing of Bextra and/or Celebrex to the Class Member; or EXHIBIT H SETTLEMENT ELIGIBILITY CRITERIA 1. PRODUCT IDENTIFICATION DOCUMENTATION In order to be eligible for compensation under the Settlement Agreement, each Claimant must provide evidence of the Class

More information

Risk Adjustment Factor (RAF) RADV June 1 st 2016

Risk Adjustment Factor (RAF) RADV June 1 st 2016 Risk Adjustment Factor (RAF) RADV June 1 st 2016 Disclaimer The information presented herein is for information purposes only. HIMS BMG Coding and Compliance Education has prepared this education using

More information

12 Lead ECGs: Ischemia, Injury & Infarction Part 2

12 Lead ECGs: Ischemia, Injury & Infarction Part 2 12 Lead ECGs: Ischemia, Injury & Infarction Part 2 McHenry Western Lake County EMS Localization: Left Coronary Artery Right Coronary Artery Right Ventricle Septal Wall Anterior Descending Artery Left Main

More information

ACSM Risk Factor Identification and Risk Stratification

ACSM Risk Factor Identification and Risk Stratification Thresholds for Use With ACSM Risk Stratification (p 24G) ACSM Risk Factor Identification and Risk Stratification By Dr. Sue Beckham, Ph.D., RCEP, PD Positive Family History Cigarette Smoking Myocardial

More information

MEDICAL POLICY SUBJECT: CARDIAC REHABILITATION. POLICY NUMBER: 8.01.14 CATEGORY: Therapy/ Rehabilitation

MEDICAL POLICY SUBJECT: CARDIAC REHABILITATION. POLICY NUMBER: 8.01.14 CATEGORY: Therapy/ Rehabilitation MEDICAL POLICY SUBJECT: CARDIAC REHABILITATION PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy

More information

Series 1 Case Studies Adverse Events that Represent Unanticipated Problems: Reporting Required

Series 1 Case Studies Adverse Events that Represent Unanticipated Problems: Reporting Required Welcome! This document contains three (3) series of Case Study examples that will demonstrate all four OHSU reporting categories (#1 4) as well as examples of events that are considered not reportable.

More information

Intrathecal Baclofen for CNS Spasticity

Intrathecal Baclofen for CNS Spasticity Intrathecal Baclofen for CNS Spasticity Last Review Date: November 13, 2015 Number: MG.MM.ME.31bC5 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or

More information

DRAFT. ICD-10 Clinical Modification Code Sets

DRAFT. ICD-10 Clinical Modification Code Sets NOTE: The tables provided below are for reference only and should not be programmed or submitted. Table 8.1 Ischemic Stroke ICD-10 Code I6300 I63011 I63012 I63019 I6302 I63031 I63032 I63039 I6309 I6310

More information

ICD-10. Clinical Concepts for Cardiology

ICD-10. Clinical Concepts for Cardiology ICD-10 Clinical Concepts for Cardiology ICD-10 Clinical Concepts Series Common Codes Clinical Documentation Tips Clinical Scenarios ICD-10 Clinical Concepts for Cardiology is a feature of Road to 10, a

More information

NAME OF THE HOSPITAL: 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3

NAME OF THE HOSPITAL: 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3 1. Name of the Procedure: Coronary Balloon Angioplasty 2. Select the Indication from the drop down of various indications

More information

The Independent Order Of Foresters ( Foresters ) Critical Illness Rider (Accelerated Death Benefit) Disclosure at the Time of Application

The Independent Order Of Foresters ( Foresters ) Critical Illness Rider (Accelerated Death Benefit) Disclosure at the Time of Application The Independent Order of Foresters ( Foresters ) - A Fraternal Benefit Society. 789 Don Mills Road, Toronto, Canada M3C 1T9 U.S. Mailing Address: P.O. Box 179 Buffalo, NY 14201-0179 T. 800 828 1540 foresters.com

More information

Angioplasty and Stent Education Guide

Angioplasty and Stent Education Guide Angioplasty and Stent Education Guide Table of Contents Treating coronary artery disease...2 What is coronary artery disease...3 Coronary artery disease treatment options...4 What are coronary artery

More information

Experience of Direct Coronary Stenting at National Institute of Cardiovascular Diseases

Experience of Direct Coronary Stenting at National Institute of Cardiovascular Diseases Experience of Direct Coronary Stenting at National Institute of Cardiovascular Diseases T. Masood,T. Sagheer,D. Jan,N. Qamar,A.M.A. Faruqui ( National Institute of Cardiovascular Diseases (NICVD), Karachi.

More information

Rivaroxaban for acute coronary syndromes

Rivaroxaban for acute coronary syndromes Northern Treatment Advisory Group Rivaroxaban for acute coronary syndromes Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) May 2014 2014 Summary Current long-term management following

More information

LCD for Noninvasive Peripheral Arterial Studies (L24339)

LCD for Noninvasive Peripheral Arterial Studies (L24339) LCD for Noninvasive Peripheral Arterial Studies (L24339) Contractor Information Contractor Name Noridian Administrative Services Contractor Number 03102 Contractor Type MAC - Part B LCD ID Number L24339

More information

ESC Guidelines on the diagnosis and treatment of peripheral artery diseases Lower extremity artery disease. Erich Minar Medical University Vienna

ESC Guidelines on the diagnosis and treatment of peripheral artery diseases Lower extremity artery disease. Erich Minar Medical University Vienna ESC Guidelines on the diagnosis and treatment of peripheral artery diseases Lower extremity artery disease Erich Minar Medical University Vienna for the Task Force on the Diagnosis and Treatment of Peripheral

More information

Associate Professor Patrick Kay Interventional cardiologist Middlemore, Auckland and Mercy Hospitals Auckland

Associate Professor Patrick Kay Interventional cardiologist Middlemore, Auckland and Mercy Hospitals Auckland Associate Professor Patrick Kay Interventional cardiologist Middlemore, Auckland and Mercy Hospitals Auckland 14:00-14:55 WS #45: New Therapies for Lipid Management 15:05-16:00 WS #57: New Therapies for

More information

Central Office N/A N/A

Central Office N/A N/A LCD ID Number L32688 LCD Title Cardiac Rehabilitation and Intensive Cardiac Rehabilitation Contractor s Determination Number L32688 AMA CPT/ADA CDT Copyright Statement CPT only copyright 2002-2011 American

More information

Optimal Diabetes Care Specifications 2013 (01/01/2012 to 12/31/2012 Dates of Service) Revised 09/19/2012

Optimal Diabetes Care Specifications 2013 (01/01/2012 to 12/31/2012 Dates of Service) Revised 09/19/2012 Summary of Changes Date of birth clarification Added language to clarify date of birth range. Please note the changes in the denominator section. Addition of Ischemic Vascular Disease ICD-9 Diagnosis Codes

More information

STROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE

STROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE STROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE CASE REPORT: ACUTE STROKE MANAGEMENT 90 YEAR OLD WOMAN, PREVIOUSLY ACTIVE AND INDEPENDENT, CHRONIC ATRIAL FIBRILLATION,

More information